2006
Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response
Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, Khoury SJ, Weiner HL. Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response. The Journal Of Immunology 2006, 177: 4196-4202. PMID: 16951385, DOI: 10.4049/jimmunol.177.6.4196.Peer-Reviewed Original ResearchConceptsMyeloid dendritic cellsDendritic cellsMultiple sclerosisInnate immune systemRR-MSImmune responseImmune systemT cell-mediated autoimmune diseaseSecondary progressive multiple sclerosisCell-mediated autoimmune diseaseStages of MSIncreased percentageProgressive phaseNeuronal degenerative changesSecondary progressive phaseSP-MS patientsProgressive multiple sclerosisProinflammatory immune responsePrimary immune responseNaive T cellsImmunologic basisTh1 responseClinical patternMS patientsPD-L1CHAPTER 46 Multiple Sclerosis
BRASS S, WEINER H, HAFLER D. CHAPTER 46 Multiple Sclerosis. 2006, 615-632. DOI: 10.1016/b978-012595961-2/50049-4.Peer-Reviewed Original ResearchSecondary progressive multiple sclerosisRelapsing-remitting multiple sclerosisPrimary progressive multiple sclerosisOligoclonal immunoglobulin bandsProgressive multiple sclerosisMultiple sclerosisCNS white matter tractSigns of MSTreatment of MSIncoordination of gaitCSF of patientsLoss of sensationWhite matter tractsOptic neuritisFiber involvementLimb weaknessMost patientsVisual lossClinical featuresImmunoglobulin bandsCommon symptomsImmunologic markersCorticospinal tractNormal glucoseAnimal models
1999
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol M, Olek M, Orav E, Stazzone L, Hafler D, Khoury S, Dawson D, Weiner H. Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease. Multiple Sclerosis Journal 1999, 5: 403-409. PMID: 10618696, DOI: 10.1177/135245859900500i606.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisDuration of progressionMultiple sclerosisProgressive diseaseSecondary progressive multiple sclerosisDuration of MSPrimary progressive patientsProgressive MS patientsPositive clinical responseOpen-label fashionClinical outcome measuresStart of treatmentOnset of diseaseMethylprednisolone therapySecondary progressiveImmunomodulatory treatmentImmunosuppressive therapyProgressive patientsClinical responsePatient characteristicsMS patientsImmunosuppressive agentsAutoimmune diseasesLabel fashionEDSS change